Weiss Robert, Buckley Kevin, Clifford Timothy
Androscoggin Cardiology Associates, Auburn, ME 04210, USA.
J Clin Hypertens (Greenwich). 2006 Oct;8(10):706-12. doi: 10.1111/j.1524-6175.2006.05615.x.
Thiazide diuretics have been recommended as one preferred choice for the initial treatment of hypertension. This study was undertaken to determine whether Maine physicians initiating monotherapy for newly diagnosed hypertensive patients from 2001-2005 used this guideline. The Maine Medicaid database was searched for the drug classes used to initiate monotherapy for patients followed for at least 6 months. A total of 5373 patients were included. In 2001, the use of beta-blockers was 23.5%, diuretics 17.5%, angiotensin-converting enzyme inhibitors 37.5%, calcium channel blockers 9.5%, angiotensin receptor blockers 3.8%, and others 8.2%. By 2005, the use of beta-blockers was 27.8%, diuretics 25.5%, angiotensin-converting enzyme inhibitors 30.9%, calcium channel blockers 6.4%, angiotensin receptor blockers 1.6%, and others 7.7%. There was an increase in the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in diabetics but no other condition affected drug choice. Although there was an increase in the use of diuretics as initial therapy in 2003 and 2004, this decreased in 2005. The increase in initial diuretic use was not reflected in patterns of ongoing antihypertensive use from 1997 to 2005. There appears to have been limited impact from the guidelines on initial drug choice and even less so on ongoing drug therapy.
噻嗪类利尿剂已被推荐作为高血压初始治疗的一种首选药物。本研究旨在确定2001年至2005年缅因州为新诊断的高血压患者启动单一疗法的医生是否遵循了该指南。在缅因州医疗补助数据库中搜索用于为随访至少6个月的患者启动单一疗法的药物类别。共纳入5373例患者。2001年,β受体阻滞剂的使用率为23.5%,利尿剂为17.5%,血管紧张素转换酶抑制剂为37.5%,钙通道阻滞剂为9.5%,血管紧张素受体阻滞剂为3.8%,其他为8.2%。到2005年,β受体阻滞剂的使用率为27.8%,利尿剂为25.5%,血管紧张素转换酶抑制剂为30.9%,钙通道阻滞剂为6.4%,血管紧张素受体阻滞剂为1.6%,其他为7.7%。糖尿病患者中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的使用有所增加,但其他情况不影响药物选择。尽管2003年和2004年利尿剂作为初始治疗的使用有所增加,但在2005年有所下降。利尿剂初始使用的增加并未反映在1997年至2005年持续的抗高血压药物使用模式中。该指南对初始药物选择的影响似乎有限,对持续药物治疗的影响更小。